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Pharmacoeconomics and outcomes analyses are
beginning to take on a much greater role with
health plans nationally in the United States.
Regence BlueShield, Washington’s largest managed
care insurer developed a new formulary review
process in 1998 [1], largely based on clinical efﬁ-
cacy, safety, outcomes, and value for money using
pharmacoeconomic modeling. Regence was the ﬁrst
large health insurer in the US to make outcomes
data and modeling a requirement for formulary
consideration. In 2000, a generalized formulary
submission format, adapted from the Regence
model, was approved by the Academy of Managed
Care Pharmacy (AMCP) with the intent of national
adoption [2].
The driving force has been that traditional for-
mulary selection processes have not stemmed the
dramatic increase in prescription drug costs over the
last decade. From any vantage point, health plans,
manufacturers, and providers are in a squeeze.
There are not enough ﬁnancial resources to meet all
needs. Providers, hospitals, labs, nursing homes,
and pharmacists want more payment for their ser-
vices. Drug costs keep going up, with no noticeable
decrease in medical costs other than for a few
exceptions, like HIV. For some health plans, drug
costs are approaching and may surpass hospital
costs; for others, drugs nearly exceed the total of all
physician and surgeon costs. At the same time,
brokers and employers don’t want to spend any
more for their health insurance, and those who
invest in pharmaceutical companies want a con-
tinued high return. Regence recognized in 1997–98
that something had to change.
From a health-plan perspective, retail drug costs
have been the single biggest factor in the “squeeze”
for resources. There are many reasons: a few break-
through medications as well as highly promoted
“me-too” products, direct to consumer advertising,
and the high cost of certain biotech drugs. New 
clinical guidelines—which health plans support—
also promote more early identiﬁcation of patients
and more aggressive prescribing for chronic afﬂic-
tions such as hyperlipidemia, diabetes, and hyper-
tension. As a notable example, prescribing by
Regence contracted physicians increased from
about 5.3 prescriptions per member per year to over
7.2 prescriptions in the past 3 years—up 35%.
Nationally, spending on prescription drugs rose by
19% in 2000 [3]. In addition, there is mounting evi-
dence for large-scale substitution of newer thera-
peutic agents for older, cheaper ones [3].
This overview examines the factors that led
Regence to develop the new formulary process in
late 1997 and to adopt it in 1998. Finally, we
examine whether the Regence format has been 
a success, and those factors that are important 
for other health plans interested in adopting the
process. Are outcomes in formulary decisions here
to stay?
Regence BlueShield Today
In 1998 [1], Regence developed a detailed unso-
licited request for information to support formulary
consideration that required pharmaceutical compa-
nies to provide evidence of clinical beneﬁt, safety
and value. The Regence message was simple: “Show
us evidence of the value of your product.” Regence
also required manufacturers to assemble their 
clinical, pharmacological, and outcomes data in a
standard format—a dossier. Without a dossier, a
new drug is not reviewed by the Regence formulary
committee. Regence clinical pharmacists administer
the pharmacy program, not pharmacy beneﬁt man-
agers (PBM), and Regence BlueShield uses an exter-
nal formulary committee. In fact, Regence staff
members have no vote, thus avoiding any percep-
tion of health plan bias in selecting products.
The formulary review process prior to 1998 was
evidence based and focused largely on the usual
FDA-required safety and efﬁcacy studies. Although
the tough, evidence-based review brought credibil-
ity to the health plan and its formulary, there were
at least three major limitations: 1) unpublished
studies and data made available to the FDA advi-
sory committees were very difﬁcult to obtain; 2) off-
label information on health beneﬁts in unapproved
indications, treatment patterns, compliance and
health economics were unevenly provided by to the
health plan by manufacturers; and 3) the search
process for clinical and economic information was
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very time consuming for Regence Pharmacy Direc-
tors to sift through the literature to support the P
& T review process with credible data.
As a result, in late 1997, the Regence formulary
submission guidelines were revised. Initial drafts
were reviewed with manufacturers’ representatives
to help ensure a process that was both realistic and
achievable. The ﬁnal guidelines were distributed in
early 1998, and later published [1]. In brief the
guidelines speciﬁed:
1. Manufacturers had to submit detailed dossiers
in a speciﬁed format, and include both pub-
lished and unpublished studies. All informa-
tion contained within the dossiers would be
treated in strict conﬁdence, supported by signed
conﬁdentiality agreements if needed by 
manufacturers.
2. Drugs without complete dossiers would not be
reviewed by the Regence P & T committee.
3. Reliable and credible evidence supporting any
company assertions on the value of the drug
would need to be provided. We sought this evi-
dence by way of encouraging the submission 
of economic analyses, outcomes data and 
modeling.
4. Regence pharmacy directors would review each
dossier, conduct an independent literature
search (to conﬁrm that the dossier included
major studies), and prepare a monograph for
the formulary committee.
During the ﬁrst 2 years, we encouraged other
health plans to make a speciﬁc request for this same
type of information. This was designed to promote
dossier standardization, which is important to 
manufacturers, and to expand the use of outcomes
data and pharmacoeconomic modeling by US
health plans. In 2000, AMCP took up this effort on
behalf of all managed care plans in the United
States.
The goals of the Regence formulary review
process include:
• developing a comprehensive, standardized, 
evidence-based process for the evaluation of clin-
ical and economic data;
• providing manufacturers with a consistent
format for providing the data needed for a sound
formulary decision;
• improving the transparency and relevance of the
available outcomes, modeling, and economic
data;
• reducing staff time required to assemble pub-
lished and unpublished reports, prepare evidence
tables, critically appraise the evidence and
prepare the formulary review monograph.
The dossier submission document includes:
• disease description, and the drug product’s role
in therapy;
• clinical efﬁcacy, safety, and effectiveness;
• economic evaluations;
• modeling, with complete transparency;
• published and unpublished studies;
• reporting bias;
• the product’s cost and value.
A detailed description of the content of RBC
dossiers is published in both our 1998 guidelines [1]
and the AMCP dossier instructions [2].
With regard to economic evaluation, we have
taken a general approach to specifying method-
ologic and reporting requirements:
1. Disease progression models are preferred. Eco-
nomic evaluations based on single randomized
controlled trials are discouraged, unless the
trial is large and/or was designed as a pragmatic
trial;
2. Models developed for other purposes or agen-
cies (e.g., NICE) are acceptable so long as they
are generally applicable to a commercial health
insurance population;
3. The economic evaluation should address the
impact of the proposed formulary changes 
on clinical outcomes, resource utilization and
costs;
4. Comparative economic evaluations are encour-
aged and budget impact models that include all
resources (not just drug costs) are welcomed as
potentially helpful;
5. Transparent presentation of results, analyses,
and model.
Impact
In 2000, Regence BlueShield received the Blue Cross
Blue Shield Association’s national award for Best
Practice in Pharmacy. In addition, a range of
managed care and formulary publications have
given wide publicity to the Regence and AMCP for-
mulary submission requirements [4–8].
Equally important, the time required for staff 
to prepare review summaries for the Regence P&T
committee has actually decreased, not counting the
initial investment in time to learn pharmacoeco-
nomics, outcomes modeling, and health outcomes.
Pharmacy Directors have invested signiﬁcant time
in training courses locally and nationally. Review of
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many dossiers, and evaluation of submitted out-
comes models has also strengthened our experience.
Regence Pharmacy Directors still continuously
update their literature database to ensure that no
key studies have been omitted from any submitted
dossier, and they carefully review and summarize
dossiers for the formulary committee.
Regence Pharmacy Director Debbie Atherly
MPH presented the results of the ﬁrst 30 months at
the 2001 ISPOR annual meeting. From January
1998 to June 2000, 51 dossiers were received. Of
those, the Regence formulary committee approved
54% of the drugs, but among those with useful 
economic models, the approval rate was 75%.
Overall, the quality of dossiers and outcomes analy-
ses has improved. As manufacturers have strength-
ened their own pharmacoeconomic departments,
Regence Blueshield has been able to maintain
increasingly higher standards for outcomes analyses
and models. At ﬁrst, some of the economic evalua-
tions were little more than cost minimization based
on acquisition costs and average wholesale prices.
Now outcomes data and models are routinely 
submitted.
The AMCP, the nation’s largest organization
focused on health-plan pharmacy programs and
formularies, has embarked on an ambitious
program to expand the use of outcomes data,
models, and dossiers. AMCP adopted the formulary
submission process with few modiﬁcations [2] in
2001, but recognizes that successful adoption will
require training of health-plan pharmacy directors
and medical directors. Few of the current genera-
tion of health-plan pharmacy leaders are trained in
pharmacoeconomics and evaluation of outcomes
models. Peter Penna, RPh, former vice president
and pharmacy director of two very large health-
plan pharmacy programs, leads the AMCP initia-
tives. An executive committee composed of AMCP
and ISPOR members provides oversight and direc-
tion. Training programs for pharmacy directors are
being scheduled throughout 2001 and 2002. Three
pilot sites have been selected for implementation 
of the AMCP/Regence formulary guidelines and 
to monitor outcomes: Premera, a health plan in
Washington; Prime Therapeutics, a pharmacy bene-
ﬁts manager in Minneapolis; and one site to be
determined.
Michael Drummond leads an ISPOR task force
that will meet with AMCP leadership to identify
how outcomes and pharmacoeconomics are cur-
rently being used by health plans and managed care
insurers and what ISPOR can do to nurture and
expand the growth and applications of pharma-
coeconomics in support of formulary decisions.
Because of Professor Drummond’s international
leadership, the Task Force report should have a sig-
niﬁcant impact on the pace of progress and ISPOR’s
role in this area.
Conclusion
The health-care system continues to be squeezed
with prescription drug cost increases being a major
factor. With the Regence and AMCP formulary sub-
mission guidelines focused on outcomes and phar-
macoeconomic models, “ﬁnding value” is becoming
increasingly important. At the most recent AMCP
national meeting, the terms “health outcomes,”
“pharmacoeconomics,” and “value” were included
in almost every presentation. The focus on value
and on health outcomes will surely increase with
initiatives, such as training programs for health-
plan pharmacy directors, supported by the AMCP
and ISPOR. Virtually every drug manufacturer has
signiﬁcantly increased their stafﬁng and expertise 
in health outcomes and pharmacoeconomics in
response to international drug review programs
such as NICE as well as the harmonized program
developed by Regence and adopted by the AMCP.
By late 2001, as this manuscript was in ﬁnal review,
every major pharmaceutical manufacturer now
submits formulary review dossiers that include
health outcomes analyses and modeling. It is the
dawn of a new evidence-based era for health plans
and their formulary committees.—D. S. Pete Fuller-
ton, PhD, Regence BlueShield, Debbie Scott Atherly,
MPH, RPh, Pharmaceutical Outcomes Research
and Policy Program, University of Washington,
Seattle, WA.
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